IDEAYA Biosciences

55 articles with IDEAYA Biosciences

• IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors Harboring GNAQ or GNA11 Mutations

  9/24/2020

  IDEAYA Biosciences, Inc. announced that it has expanded its clinical trial collaboration and supply agreement with Pfizer Inc. for an IDEAYA sponsored clinical combination study of IDE196, a Protein Kinase C inhibitor, and crizotinib, a cMET inhibitor to which Pfizer has exclusive worldwide rights.

• IDEAYA to Participate in Upcoming September 2020 Investor Relations Events

  8/31/2020

  IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced that management will present at the following upcoming investor relations events.

• IDEAYA Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update

  8/12/2020

  Established strategic partnership with GlaxoSmithKline on Synthetic Lethality programs MAT2A, Pol Theta and Werner Helicase

• IDEAYA Announces HSR Clearance of GSK Strategic Partnership in Synthetic Lethality and Closing of Glaxo Group Equity Investment

  8/4/2020

  Collaboration, Option and License Agreement Effective following HSR Clearance and $100 Million Up-Front Payment received by IDEAYA

• IDEAYA Announces IDE196 Program Update and Clinical Protocol Criteria Met for Cohort Expansion in Skin Melanoma for Phase 2 GNAQ/11 Basket Trial

  7/16/2020

  4 evaluable GNAQ/11 mutation skin melanoma patients enrolled in Stage 1 cohort with a 100% Disease Control Rate (excluding 1 non-evaluable) and 1 confirmed partial response by RECIST 1.1 guidelines

• IDEAYA to Participate in Fireside Chat at BTIG Biotechnology Conference and Wedbush PacGrow Healthcare Conference on August 11 and 12, 2020

  7/14/2020

  IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced the Company will participate in the following upcoming investor conferences

• IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Binimetinib, a MEK Inhibitor

  7/9/2020

  IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced First-Patient-In in the Phase 1 combination study of IDE196 and binimetinib, a MEK inhibitor, in metastatic uveal melanoma.

• IDEAYA Appoints Garret Hampton, Ph.D., to the Board of Directors, an Industry Leader in Precision Medicine Oncology and Diagnostics

  6/30/2020

  IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics based on Synthetic Lethality, announced the appointment of Garret Hampton, Ph.D., to its Board of Directors.

• IDEAYA Announces Pricing of Public Offering of Common Stock

  6/17/2020

  IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions.

• IDEAYA Announces Proposed Public Offering of Common Stock

  6/16/2020

  IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $60 million of shares of its common stock in an underwritten public offering.

• IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine Oncology

  6/16/2020

  Partnership covers three IDEAYA Synthetic Lethality programs - MAT2A, Pol Theta and Werner Helicase, and will explore combinations between IDEAYA and GSK programs

• 

  GSK Dives Deeper into Synthetic Lethality with IDEAYA Biosciences

  6/16/2020

  The two companies will explore potential oncology treatments with emerging technology.

• IDEAYA Biosciences Selected to Join Russell 3000® Index

  6/11/2020

  IDEAYA Biosciences, Inc. is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.

• IDEAYA Announces Nomination of Development Candidate, IDE397, for MAT2A Synthetic Lethality Program Targeting MTAP-Deletion Patient Population

  6/8/2020

  IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, announced that it has selected development candidate, IDE397, for its Methionine adenosyltransferase 2a Synthetic Lethality program.

• IDEAYA Biosciences to Participate in Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020

  5/19/2020

  IDEAYA Biosciences, Inc. announced that Yujiro S. Hata, Chief Executive Officer and President at IDEAYA Biosciences, is scheduled to participate in a fireside chat discussion hosted by Maury Raycroft, Ph.D., Equity Analyst, at the Jefferies Virtual Healthcare Conference on Tues, June 2, 2020 at 11:00 a.m. ET.

• IDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ/11 Tumors and Preclinical MAT2A Synthetic Lethality Program

  5/15/2020

  IDEAYA Biosciences, Inc. is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.

• IDEAYA Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Business Update

  5/12/2020

  IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, provided a business update and announced financial results for the first quarter ended March 31, 2020 .

• IDEAYA Biosciences Announces Addition of Julie Patel as Vice President, Human Resources, Enhancing its Leadership Team

  4/21/2020

  IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, announced that Julie Patel has joined the company as Vice President, Human Resources.

• IDEAYA Biosciences, Inc. Reports Fourth Quarter 2019 Financial Results and Provides Business Update

  3/24/2020

  IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, provided a business update and announced financial results for the fourth quarter ended December 31, 2019.

• IDEAYA Biosciences Announces IDE196 Monotherapy Phase 2 Dose Selection and Clinical Program Update

  3/18/2020

  IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announces an update for IDE196, a Protein Kinase C inhibitor, in its ongoing Phase 1/2 clinical trial entitled "A Phase 1/2 Study in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions".